Fig. 2From: CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activationPalbociclib inhibition of morphological changes associated with activation in mast cells. Anti-DNP IgE-sensitized BLCs were pretreated (or not) with palbociclib for 1 h and then challenged with DNP-HSA (100 ng/ml) for 30 min. a Toluidine blue-stained RBCs. Blue arrows indicate irregular cell morphology and the release purple particles. b The statistical data were from 3 independent experiments. c FITC-phalloidin stained BLCs. Red arrow indicates cell morphology irregularity due to decomposition of F-actin cytoskeleton. d The data are summarized from 3 independent experiments, *p < 0.05, **p < 0.01, compared to the HSA-DNP groupBack to article page